DecisionDx-Melanoma Test Outperforms Traditional Staging in Key Study, Validating Patient Care
Summary
Castle Biosciences announced the publication of a prospective, multi-center study in Future Oncology, demonstrating that its DecisionDx-Melanoma i31-SLNB test significantly outperforms traditional staging criteria in identifying cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy (SLNB). The study, involving 912 patients, showed the test accurately identifies low-risk patients with a 2.6% nodal positivity rate and a 97.8% three-year recurrence-free survival, aligning with NCCN guidelines. Furthermore, the test achieved a true-negative to false-negative ratio of 55:1 in T1-T2a patients, far exceeding the 19:1 guideline benchmark, indicating superior precision and fewer missed positive nodes. This strong clinical validation for a core product is a material positive development, especially following the company's recent financial challenges highlighted in its 10-K. Investors will be watching for increased adoption and potential positive impacts on reimbursement and market share.
At the time of this announcement, CSTL was trading at $25.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $756.4M. The 52-week trading range was $14.59 to $44.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.